Replimune Group, Inc.
Close on Oct 19, 2026
- Market cap
- $1.07B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2027 Ended Jun 30, 2026 | Aug 14, 2026 | Before market open | – | – | – |
| Q4 FY2026 Ended Mar 31, 2026 | Jun 29, 2026 | Before market open | – | – | – |
| Q3 FY2026 Ended Dec 31, 2025 | Feb 3, 2026 | Before market open | – | $-0.77 | – |
| Q2 FY2026 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | – | – | – |
| Q1 FY2026 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | – | $-0.95 | – |
| Q4 FY2025 Ended Mar 31, 2025 | May 22, 2025 | Before market open | – | – | – |
| Q3 FY2025 Ended Dec 31, 2024 | Feb 12, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | – | – |
| Q1 FY2025 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | $-0.78 | – |
| Q4 FY2024 Ended Mar 31, 2024 | May 16, 2024 | Before market open | – | – | – |
| Q3 FY2024 Ended Dec 31, 2023 | Feb 8, 2024 | Before market open | – | $-0.77 | – |
Press releases
Announcements Replimune filed with the SEC
Reports Fiscal First Quarter 2027 Financial Results and Provides
Results of operations · EX-99.1 to Form 8-K
Replimune Announces Pricing of $150.0 Million
Other events · EX-99.1 to Form 8-K
Announces FDA Accelerated Approval of TUDRIQEV TM in Combination with Nivolumab for Unresectable Advanced Cutaneous
Other events · EX-99.1 to Form 8-K
© 2026 Replimune Group Inc. TUDRIQEV TM (vusolimogene oderparepvec - wtpg ) FDA Accelerated Approval Investor Call August 6, 2026
Other events · EX-99.2 to Form 8-K
Replimune Announces Favorable Outcome of FDA's Cellular,
Other events · EX-99.1 to Form 8-K
in Combination with Nivolumab for the Treatment of
Regulation FD disclosure · EX-99.1 to Form 8-K
Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Replimune Announces FDA Acceptance of RP1 Biologics
Regulation FD disclosure · EX-99.1 to Form 8-K
Replimune Announces Planned RP1 BLA Resubmission Following Productive
Regulation FD disclosure · EX-99.1 to Form 8-K
Replimune Receives Complete Response Letter
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Replimune Reports Fiscal Third Quarter 2026
Material agreement · Results of operations · New financial obligation · EX-99.1 to Form 8-K
Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Replimune Announces FDA Acceptance of BLA Resubmission
Other events · EX-99.1 to Form 8-K
Replimune Provides Update Following Type A Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Replimune Announces Type A Meeting Scheduled with FDA
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Replimune Reports Fiscal First Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Replimune Receives Complete Response Letter
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Replimune Reports Fiscal Fourth Quarter and
Results of operations · EX-99.1 to Form 8-K
Replimune Reports Fiscal Third Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Replimune Announces Biologics License Application Acceptance and
Other events · EX-99.1 to Form 8-K
Replimune Announces Proposed Public Offering
Other events · EX-99.1 to Form 8-K
Replimune Announces Pricing of Upsized Public
Other events · EX-99.2 to Form 8-K
Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Replimune Reports Fiscal Second Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Replimune Reports Fiscal First Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Replimune Announces $100 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
IGNYTE Investor Event (6/6/24) 1
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Positive Data from RP1 and RP2 Clinical Programs at the 2024
Other events · EX-99.1 to Form 8-K
Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Replimune Announces Appointment of Sushil Patel
Executive or director change · Other events · EX-99.1 to Form 8-K
Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended,
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from
Other events · EX-99.1 to Form 8-K
Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Replimune Announces Appointment of Emily Hill
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB099280 in Patients with Cutaneous Squamous
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Replimune Announces Sander Slootweg will Depart
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K